PT  - JOURNAL ARTICLE
AU  - Castelán-Sánchez, Hugo G.
AU  - Martínez-Castilla, León P.
AU  - Sganzerla-Martínez, Gustavo
AU  - Torres-Flores, Jesús
AU  - López-Leal, Gamaliel
TI  - Genome evolution and early introductions of the SARS-CoV-2 Omicron Variant in Mexico
AID  - 10.1101/2022.07.13.22277603
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.13.22277603
4099  - http://medrxiv.org/content/early/2022/07/15/2022.07.13.22277603.short
4100  - http://medrxiv.org/content/early/2022/07/15/2022.07.13.22277603.full
AB  - A new variant of SARS-CoV-2 Omicron (Pango lineage designation B.1.1.529), was first reported to the World Health Organization (WHO) by South African health authorities on November 24, 2021. The Omicron variant possesses numerous mutations associated with increased transmissibility and immune escape properties. In November 2021, Mexican authorities reported Omicron’s presence in the country. In this study, we infer the first introductory events of Omicron and the impact that human mobility can have on the spread of the virus. We also evaluated the adaptive evolutionary processes in Mexican SARS-CoV-2 genomes during the first month of circulation of Omicron.We infer 173 introduction events of Omicron in Mexico in the first two months of detection; subsequently, of the introductions, there was an increase in the prevalence for January.This higher prevalence of the novel variant results in a peak of cases reported, on average, six weeks after a higher mobility trend was reported. The peak of cases reported is due to the BA.1.1 Omicron sub-lineage dominated, followed by BA.1 and BA.15 sub-lineages in the country from January to February 2022.Additionally, we identified the presence of diversifying natural selection in the genomes of Omicron and found mainly five non-synonymous mutations in the RDB domain of the Spike protein, all of them related to evasion of the immune response. In contrast, the other proteins in the genome are highly conserved—however, there are homoplasies mutations in non-structural proteins, indicating a parallel evolution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript